The NUVISAN group, an international service provider for clinical studies, contract development and manufacturing (CRO/CDMO) with headquarters in Neu-Ulm, has acquired the Munich company Inamed GmbH. Ascenion’s oldest portfolio company has thus found the ideal partner with which to continue its more than 20 year-old success story. The Inamed team, which is being taken on long-term in its entirety, brings specific expertise in the area of respiratory and rare diseases to NUVISAN. Inamed is one of the few contract research organisations capable of analysing the flow profile of orally inhaled drugs, and also has access to patient groups that are very difficult to recruit.
This enables NUVISAN to offer its clients an extended spectrum of services and greater capacity. The company now has over 160 beds available at two locations. Overall, NUVISAN has six locations for clinical development and production in Germany and France, and additional offices in Brazil, Argentina, Peru and the USA.
For further information see NUVISAN's press release.